Cargando…

Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma

Epidermal growth factor receptor (EGFR) and tumour growth factor alpha (TGFα) are frequently overexpressed in renal cell carcinoma (RCC) yet responses to single-agent EGFR inhibitors are uncommon. Although von Hippel–Lindau (VHL) mutations are predominant, RCC also develops in individuals with tuber...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gemmill, R M, Zhou, M, Costa, L, Korch, C, Bukowski, R M, Drabkin, H A
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2005
Materias:	Genetics and Genomics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361810/ https://www.ncbi.nlm.nih.gov/pubmed/15956968 http://dx.doi.org/10.1038/sj.bjc.6602646

Ejemplares similares

Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene
por: Wykoff, C C, et al.
Publicado: (2004)

Determination of the consequences of VHL mutations on VHL transcripts in renal cell carcinoma
por: TAYLOR, CLAIRE, et al.
Publicado: (2012)

Pooled genome-wide CRISPR activation screening for rapamycin resistance genes in Drosophila cells
por: Xia, Baolong, et al.
Publicado: (2023)

Renal cancer and pneumothorax risk in Birt–Hogg–Dubé syndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families
por: Houweling, A C, et al.
Publicado: (2011)

Frequent Mutations of VHL Gene and the Clinical Phenotypes in the Largest Chinese Cohort With Von Hippel–Lindau Disease
por: Hong, Baoan, et al.
Publicado: (2019)

Synergistic Inhibition of Survival, Proliferation, and Migration of U87 Cells with a Combination of LY341495 and Iressa
por: Yelskaya, Zarina, et al.
Publicado: (2013)

Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)
por: Kimura, H, et al.
Publicado: (2007)

Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections
por: Wambaugh, Morgan A, et al.
Publicado: (2020)

Somatic glypican 3 (GPC3) mutations in Wilms' tumour
por: White, G R M, et al.
Publicado: (2002)

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA)
por: Kokubo, Y, et al.
Publicado: (2005)

Functional epigenomics approach to identify methylated candidate tumour suppressor genes in renal cell carcinoma
por: Morris, M R, et al.
Publicado: (2008)

The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website
por: Bamford, S, et al.
Publicado: (2004)

Investigations on a clinically and functionally unusual and novel germline p53 mutation
por: Rutherford, J, et al.
Publicado: (2002)

Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis
por: Pabst, T, et al.
Publicado: (2009)

Toxins, mutations and adaptations
por: De Jong, Maarten, et al.
Publicado: (2021)

Mutation analysis of the MSMB gene in familial prostate cancer
por: Kote-Jarai, Z, et al.
Publicado: (2010)

GNAQ and GNA11 mutations and downstream YAP activation in choroidal nevi
por: Vader, M J C, et al.
Publicado: (2017)

TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations
por: Labussière, M, et al.
Publicado: (2014)

Germline BRCA1 mutations increase prostate cancer risk
por: Leongamornlert, D, et al.
Publicado: (2012)

Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients
por: Zajkowicz, A, et al.
Publicado: (2015)

Analysis of human prostate cancers and cell lines for mutations in the TP53 and KLF6 tumour suppressor genes
por: Mühlbauer, K-R, et al.
Publicado: (2003)

Somatic mutations of KIT in familial testicular germ cell tumours
por: Rapley, E A, et al.
Publicado: (2004)

Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity
por: Robey, R W, et al.
Publicado: (2003)

Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis
por: Edwards, S M, et al.
Publicado: (2010)

SLIT2 promoter methylation analysis in neuroblastoma, Wilms' tumour and renal cell carcinoma
por: Astuti, D, et al.
Publicado: (2004)

A novel germline mutation of PTEN associated with brain tumours of multiple lineages
por: Staal, F J T, et al.
Publicado: (2002)

The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer
por: Akbari, M R, et al.
Publicado: (2014)

Target gene selectivity of hypoxia-inducible factor-α in renal cancer cells is conveyed by post-DNA-binding mechanisms
por: Lau, K W, et al.
Publicado: (2007)

Genetic and Epigenetic Mechanisms Deregulate the CRL2(pVHL) Complex in Hepatocellular Carcinoma
por: Minatel, Brenda C., et al.
Publicado: (2022)

Absence of truncating BRIP1 mutations in chromosome 17q-linked hereditary prostate cancer families
por: Ray, A M, et al.
Publicado: (2009)

Elimination of wild-type P53 mRNA in glioblastomas showing heterozygous mutations of P53
por: Szybka, M, et al.
Publicado: (2008)

CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma
por: McRonald, Fiona E, et al.
Publicado: (2009)

Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors
por: Blackledge, G, et al.
Publicado: (2004)

The R72P P53 mutation is associated with familial breast cancer in Jewish women
por: Ohayon, T, et al.
Publicado: (2005)

MSH6 germline mutations in early-onset colorectal cancer patients without family history of the disease
por: Pinto, C, et al.
Publicado: (2006)

Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma
por: Mezzapelle, R, et al.
Publicado: (2013)

Early p53 mutations in nondysplastic Barrett's tissue detected by the restriction site mutation (RSM) methodology
por: Jenkins, G J S, et al.
Publicado: (2003)

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer
por: Birkeland, E, et al.
Publicado: (2012)

Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma
por: Dono, M, et al.
Publicado: (2014)

The G67E mutation in hMLH1 is associated with an unusual presentation of Lynch syndrome
por: Clyne, M, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_03vh6ejpa5pi42k3mdbpq7ril7